Pyoderma gangrenosum - Rebel without a cure?

Sharon E. Jacob, Robyn S. Weisman, Francisco A. Kerdel

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Pyoderma gangrenosum (PG) is a rare neutrophilic, ulcerating dermatosis that is frequently difficult to diagnose and often a diagnosis of exclusion. It is hypothesized that PG may be caused by an abnormal T-cell and neutrophil response, which correlates with its common link to other disorders, such as inflammatory bowel disease, rheumatoid arthritis, and malignancies. Several treatments have been used successfully for PG, but none has proven to be universally effective. Methods: We present three cases of PG treated with adalimumab after failed courses of steroids (orally and parenterally), thalidomide, cyclosporine, and mycophenolate mofetil. Results: Patients 2 and 3, who had previously responded to infliximab, albeit with recurrence, were successfully treated with adalimumab at a dose of 40 mg once a week. Patient 1 initially responded to adalimumab, but after 7.5 months failed to show wound bed improvement at a dose of 80 mg/week subcutaneously. This patient had not previously been treated with infliximab. Conclusion: We believe adalimumab to be a valuable alternative for the treatment of PG, with comparable efficacy to infliximab.

Original languageEnglish
Pages (from-to)192-194
Number of pages3
JournalInternational Journal of Dermatology
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Pyoderma Gangrenosum
Mycophenolic Acid
Thalidomide
Inflammatory Bowel Diseases
Skin Diseases
Cyclosporine
Rheumatoid Arthritis
Neutrophils
Steroids
T-Lymphocytes
Recurrence
Adalimumab
Wounds and Injuries
Therapeutics
Infliximab
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Pyoderma gangrenosum - Rebel without a cure? / Jacob, Sharon E.; Weisman, Robyn S.; Kerdel, Francisco A.

In: International Journal of Dermatology, Vol. 47, No. 2, 01.02.2008, p. 192-194.

Research output: Contribution to journalArticle

Jacob, Sharon E. ; Weisman, Robyn S. ; Kerdel, Francisco A. / Pyoderma gangrenosum - Rebel without a cure?. In: International Journal of Dermatology. 2008 ; Vol. 47, No. 2. pp. 192-194.
@article{91104ef6f03242a4970001ea64c4a6ae,
title = "Pyoderma gangrenosum - Rebel without a cure?",
abstract = "Background: Pyoderma gangrenosum (PG) is a rare neutrophilic, ulcerating dermatosis that is frequently difficult to diagnose and often a diagnosis of exclusion. It is hypothesized that PG may be caused by an abnormal T-cell and neutrophil response, which correlates with its common link to other disorders, such as inflammatory bowel disease, rheumatoid arthritis, and malignancies. Several treatments have been used successfully for PG, but none has proven to be universally effective. Methods: We present three cases of PG treated with adalimumab after failed courses of steroids (orally and parenterally), thalidomide, cyclosporine, and mycophenolate mofetil. Results: Patients 2 and 3, who had previously responded to infliximab, albeit with recurrence, were successfully treated with adalimumab at a dose of 40 mg once a week. Patient 1 initially responded to adalimumab, but after 7.5 months failed to show wound bed improvement at a dose of 80 mg/week subcutaneously. This patient had not previously been treated with infliximab. Conclusion: We believe adalimumab to be a valuable alternative for the treatment of PG, with comparable efficacy to infliximab.",
author = "Jacob, {Sharon E.} and Weisman, {Robyn S.} and Kerdel, {Francisco A.}",
year = "2008",
month = "2",
day = "1",
doi = "10.1111/j.1365-4632.2008.03412.x",
language = "English",
volume = "47",
pages = "192--194",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pyoderma gangrenosum - Rebel without a cure?

AU - Jacob, Sharon E.

AU - Weisman, Robyn S.

AU - Kerdel, Francisco A.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: Pyoderma gangrenosum (PG) is a rare neutrophilic, ulcerating dermatosis that is frequently difficult to diagnose and often a diagnosis of exclusion. It is hypothesized that PG may be caused by an abnormal T-cell and neutrophil response, which correlates with its common link to other disorders, such as inflammatory bowel disease, rheumatoid arthritis, and malignancies. Several treatments have been used successfully for PG, but none has proven to be universally effective. Methods: We present three cases of PG treated with adalimumab after failed courses of steroids (orally and parenterally), thalidomide, cyclosporine, and mycophenolate mofetil. Results: Patients 2 and 3, who had previously responded to infliximab, albeit with recurrence, were successfully treated with adalimumab at a dose of 40 mg once a week. Patient 1 initially responded to adalimumab, but after 7.5 months failed to show wound bed improvement at a dose of 80 mg/week subcutaneously. This patient had not previously been treated with infliximab. Conclusion: We believe adalimumab to be a valuable alternative for the treatment of PG, with comparable efficacy to infliximab.

AB - Background: Pyoderma gangrenosum (PG) is a rare neutrophilic, ulcerating dermatosis that is frequently difficult to diagnose and often a diagnosis of exclusion. It is hypothesized that PG may be caused by an abnormal T-cell and neutrophil response, which correlates with its common link to other disorders, such as inflammatory bowel disease, rheumatoid arthritis, and malignancies. Several treatments have been used successfully for PG, but none has proven to be universally effective. Methods: We present three cases of PG treated with adalimumab after failed courses of steroids (orally and parenterally), thalidomide, cyclosporine, and mycophenolate mofetil. Results: Patients 2 and 3, who had previously responded to infliximab, albeit with recurrence, were successfully treated with adalimumab at a dose of 40 mg once a week. Patient 1 initially responded to adalimumab, but after 7.5 months failed to show wound bed improvement at a dose of 80 mg/week subcutaneously. This patient had not previously been treated with infliximab. Conclusion: We believe adalimumab to be a valuable alternative for the treatment of PG, with comparable efficacy to infliximab.

UR - http://www.scopus.com/inward/record.url?scp=38349181566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349181566&partnerID=8YFLogxK

U2 - 10.1111/j.1365-4632.2008.03412.x

DO - 10.1111/j.1365-4632.2008.03412.x

M3 - Article

C2 - 18211497

AN - SCOPUS:38349181566

VL - 47

SP - 192

EP - 194

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 2

ER -